Sort
10,766 grants matching “checkpoint inhibitor”
MMS22L loss and PARP inhibition in prostate cancer
$409,463Li Jia · Brigham And Women'S Hospital · R01 · FY2025 · CA
Immuno-Targeted Therapy for Melanoma
$409,323Antoni Ribas · University Of California Los Angeles · R35 · FY2015 · CA
Project 1: Decoding, Modeling and Targeting Oncohistones and an Oncohistone-like Protein
$409,292Nada Jabado · Rockefeller University · P01 · FY2024 · CA
Mre11-Dependent DNA Damage Responses in Breast Cancer Pathogenesis
$409,161Gaorav P. Gupta · Univ Of North Carolina Chapel Hill · R37 · FY2019 · CA
Mre11-Dependent DNA Damage Responses in Breast Cancer Pathogenesis
$409,161Gaorav P. Gupta · Univ Of North Carolina Chapel Hill · R37 · FY2021 · CA
Mre11-Dependent DNA Damage Responses in Breast Cancer Pathogenesis
$409,161Gaorav P. Gupta · Univ Of North Carolina Chapel Hill · R37 · FY2020 · CA
Enhancing anti-PD-1 blockade antitumor efficacy by oncolytic virotherapy-mediated tumor microenvironment immunomodulation
$409,158Jorge G Gomez-Gutierrez · University Of Missouri-Columbia · R21 · FY2025 · CA
REGULATION AND ADAPTIVE MECHANISMS OF ONCOGENIC RAS/ERK SIGNALING
$408,974Poulikos I Poulikakos · Icahn School Of Medicine At Mount Sinai · R01 · FY2022 · CA
REGULATION AND ADAPTIVE MECHANISMS OF ONCOGENIC RAS/ERK SIGNALING
$408,974Poulikos I Poulikakos · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · CA
The coordination of cell size control and cell cycle regulation at developmental extremes
$408,958Amanda A Amodeo · Dartmouth College · R35 · FY2023 · GM
Engineered Ensemble Nanoimmunotherapies for Cancer
$408,831Rohan Fernandes · George Washington University · R37 · FY2021 · CA
Immune activation by necroptotic cell death
$408,808Andrew Atwell Oberst · University Of Washington · R01 · FY2022 · CA
A Novel ULK1 Pathway as a New Therapeutic Target in Melanoma
$408,596Diana Nora Vaz Saleiro · Northwestern University At Chicago · R21 · FY2020 · CA
Elucidating the critical role of Wee1 in GIST
$408,548Lori Rink · Research Inst Of Fox Chase Can Ctr · R01 · FY2024 · CA
The function and regulation of the C. elegans Haspin histone kinase homolog, HASP-1
$408,521David J Wynne · University Of Portland · R15 · FY2023 · GM
Project 4: Interrogating and harnessing age-related IFN signaling and innate immunity in HCC prevention and therapy
$408,425Gen-Sheng Feng · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2023 · AG
Project 1:Therapeutically improving HNSCC antigenicity through epigenetic reprogramming
$408,242Sara Isabel Pai · Massachusetts General Hospital · P01 · FY2020 · CA
Project 1:Therapeutically improving HNSCC antigenicity through epigenetic reprogramming
$408,242Sara Isabel Pai · Massachusetts General Hospital · P01 · FY2021 · CA
Project 1:Therapeutically improving HNSCC antigenicity through epigenetic reprogramming
$408,242Sara Isabel Pai · Massachusetts General Hospital · P01 · FY2019 · CA
Project 2: Redirecting pre-existing anti-viral immunity to HNSCCs with APECs
$408,240Thorsten Roman Mempel · Massachusetts General Hospital · P01 · FY2021 · CA
Project 2: Redirecting pre-existing anti-viral immunity to HNSCCs with APECs
$408,238Mark Cobbold · Massachusetts General Hospital · P01 · FY2020 · CA
Project 2: Redirecting pre-existing anti-viral immunity to HNSCCs with APECs
$408,238Mark Cobbold · Massachusetts General Hospital · P01 · FY2019 · CA
ALDH Inhibition as Modulator of Tumor Immunobiology
$408,231Ronald J Buckanovich · Magee-Women'S Res Inst And Foundation · R01 · FY2024 · CA
Project 1
$408,054Ashraf S. Ibrahim · Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center · P01 · FY2025 · AI
Tumor microenvironment-dependent therapy resistance
$407,872Shahab Asgharzadeh · Children'S Hosp Of Philadelphia · P01 · FY2025 · CA